Taka-Diastase
Order now: dominika@ksiazkiwnauce.pl
Lysinoalanine · 2 HCl (diastereomeric mixture: LL + LD) |
|||
F-1195.0250 | Bachem | 250.0mg | 1371.6 EUR |
Description: Sum Formula: C9H19N3O4·2HCl; CAS# [4418-81-9] |
|||
2-Di-1-ASP |
|||
HY-135009 | MedChemExpress | 10mM/1mL | 135.6 EUR |
4-(4-(Dimethylamino)-styryl)-N-methylpyridinium iodide (4-Di-1-ASP) |
|||
70006 | Biotium | 500MG | 163.2 EUR |
Description: Minimum order quantity: 1 unit of 500MG |
|||
Tak-438 |
|||
abx188897-1g | Abbexa | 1 g | 1813.2 EUR |
TAK-901 |
|||
B1945-25 | Biovision | each | 1005.6 EUR |
TAK-901 |
|||
B1945-5 | Biovision | each | 301.2 EUR |
TAK-700 |
|||
B2209-5 | Biovision | each | 248.4 EUR |
TAK-593 |
|||
B3268-10 | ApexBio | 10 mg | 602.4 EUR |
Description: TAK-593 is a highly potent inhibitor of VEGFR2 with IC50 value of 0.95nM [1].TAK-593 is an imidazo [1, 2-b] pyridazine derivative. It is found to inhibit VEGFR2 with a highly potent effect in the non-RI assay using the AlphaScreen system. |
|||
TAK-593 |
|||
B3268-100 | ApexBio | 100 mg | 2666.4 EUR |
Description: TAK-593 is a highly potent inhibitor of VEGFR2 with IC50 value of 0.95nM [1].TAK-593 is an imidazo [1, 2-b] pyridazine derivative. It is found to inhibit VEGFR2 with a highly potent effect in the non-RI assay using the AlphaScreen system. |
|||
TAK-593 |
|||
B3268-5 | ApexBio | 5 mg | 385.2 EUR |
Description: TAK-593 is a highly potent inhibitor of VEGFR2 with IC50 value of 0.95nM [1].TAK-593 is an imidazo [1, 2-b] pyridazine derivative. It is found to inhibit VEGFR2 with a highly potent effect in the non-RI assay using the AlphaScreen system. |
|||
TAK-593 |
|||
B3268-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 417.6 EUR |
Description: TAK-593 is a highly potent inhibitor of VEGFR2 with IC50 value of 0.95nM [1].TAK-593 is an imidazo [1, 2-b] pyridazine derivative. It is found to inhibit VEGFR2 with a highly potent effect in the non-RI assay using the AlphaScreen system. |
|||
TAK-593 |
|||
B3268-50 | ApexBio | 50 mg | 1752 EUR |
Description: TAK-593 is a highly potent inhibitor of VEGFR2 with IC50 value of 0.95nM [1].TAK-593 is an imidazo [1, 2-b] pyridazine derivative. It is found to inhibit VEGFR2 with a highly potent effect in the non-RI assay using the AlphaScreen system. |
|||
TAK-715 |
|||
B1701-25 | Biovision | each | 757.2 EUR |
TAK-715 |
|||
B1701-5 | Biovision | each | 235.2 EUR |
TAK-733 |
|||
B1621-10 | ApexBio | 10 mg | 373.2 EUR |
Description: TAK-733 is a potent, ATP-noncompetitive and selective inhibitor of MEK allosteric site with the IC50 value of 3.2nM [1]. |
|||
TAK-733 |
|||
B1621-5 | ApexBio | 5 mg | 226.8 EUR |
Description: TAK-733 is a potent, ATP-noncompetitive and selective inhibitor of MEK allosteric site with the IC50 value of 3.2nM [1]. |
|||
TAK-733 |
|||
B1621-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 234 EUR |
Description: TAK-733 is a potent, ATP-noncompetitive and selective inhibitor of MEK allosteric site with the IC50 value of 3.2nM [1]. |
|||
TAK-733 |
|||
B1621-50 | ApexBio | 50 mg | 1005.6 EUR |
Description: TAK-733 is a potent, ATP-noncompetitive and selective inhibitor of MEK allosteric site with the IC50 value of 3.2nM [1]. |
|||
TAK960 |
|||
B5860-10 | ApexBio | 10 mg | 303.6 EUR |
Description: Description:IC50: 8.4 to 46.9 nmol/L for multiple cancer cell linesPolo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key mitosis processes. |
|||
TAK960 |
|||
B5860-5 | ApexBio | 5 mg | 226.8 EUR |
Description: Description:IC50: 8.4 to 46.9 nmol/L for multiple cancer cell linesPolo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key mitosis processes. |
|||
TAK960 |
|||
B5860-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 282 EUR |
Description: Description:IC50: 8.4 to 46.9 nmol/L for multiple cancer cell linesPolo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key mitosis processes. |
|||
TAK960 |
|||
B5860-50 | ApexBio | 50 mg | 811.2 EUR |
Description: Description:IC50: 8.4 to 46.9 nmol/L for multiple cancer cell linesPolo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key mitosis processes. |
|||
TAK-733 |
|||
2460-25 | Biovision | each | 966 EUR |
TAK-733 |
|||
2460-5 | Biovision | each | 288 EUR |
TAK-632 |
|||
2473-25 | Biovision | each | 692.4 EUR |
TAK-632 |
|||
2473-5 | Biovision | each | 222 EUR |
TAK-242 |
|||
A3850-10 | ApexBio | 10 mg | 309.6 EUR |
Description: IC50: With IC50 of 1.1 to 11 nM, TAK-242 inhibited LPS-induced NO production, tumor necrosis factor-alpha and interleukin (IL)-6 in RAW264.7 cells and mouse peritoneal macrophages [1]. |
|||
TAK-242 |
|||
A3850-100 | ApexBio | 100 mg | 1730.4 EUR |
Description: IC50: With IC50 of 1.1 to 11 nM, TAK-242 inhibited LPS-induced NO production, tumor necrosis factor-alpha and interleukin (IL)-6 in RAW264.7 cells and mouse peritoneal macrophages [1]. |
|||
TAK-242 |
|||
A3850-5 | ApexBio | 5 mg | 226.8 EUR |
Description: IC50: With IC50 of 1.1 to 11 nM, TAK-242 inhibited LPS-induced NO production, tumor necrosis factor-alpha and interleukin (IL)-6 in RAW264.7 cells and mouse peritoneal macrophages [1]. |
|||
TAK-242 |
|||
A3850-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 243.6 EUR |
Description: IC50: With IC50 of 1.1 to 11 nM, TAK-242 inhibited LPS-induced NO production, tumor necrosis factor-alpha and interleukin (IL)-6 in RAW264.7 cells and mouse peritoneal macrophages [1]. |
|||
TAK-242 |
|||
A3850-50 | ApexBio | 50 mg | 1034.4 EUR |
Description: IC50: With IC50 of 1.1 to 11 nM, TAK-242 inhibited LPS-induced NO production, tumor necrosis factor-alpha and interleukin (IL)-6 in RAW264.7 cells and mouse peritoneal macrophages [1]. |
|||
TAK-901 |
|||
A4124-10 | ApexBio | 10 mg | 324 EUR |
Description: IC50: 0.0017, 0.021 for Aurora-B/INCENP and Aurora-A/TPX2, respectivelyProtein kinases Aurora A, B, and C play crucial roles during mitosis and cell division, are frequently elevated in cancer, and represent attractive targets for therapeutic intervention. |
|||
TAK-901 |
|||
A4124-200 | ApexBio | 200 mg | 2133.6 EUR |
Description: IC50: 0.0017, 0.021 for Aurora-B/INCENP and Aurora-A/TPX2, respectivelyProtein kinases Aurora A, B, and C play crucial roles during mitosis and cell division, are frequently elevated in cancer, and represent attractive targets for therapeutic intervention. |
|||
TAK-901 |
|||
A4124-5 | ApexBio | 5 mg | 212.4 EUR |
Description: IC50: 0.0017, 0.021 for Aurora-B/INCENP and Aurora-A/TPX2, respectivelyProtein kinases Aurora A, B, and C play crucial roles during mitosis and cell division, are frequently elevated in cancer, and represent attractive targets for therapeutic intervention. |
|||
TAK-901 |
|||
A4124-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 226.8 EUR |
Description: IC50: 0.0017, 0.021 for Aurora-B/INCENP and Aurora-A/TPX2, respectivelyProtein kinases Aurora A, B, and C play crucial roles during mitosis and cell division, are frequently elevated in cancer, and represent attractive targets for therapeutic intervention. |
|||
TAK-901 |
|||
A4124-50 | ApexBio | 50 mg | 880.8 EUR |
Description: IC50: 0.0017, 0.021 for Aurora-B/INCENP and Aurora-A/TPX2, respectivelyProtein kinases Aurora A, B, and C play crucial roles during mitosis and cell division, are frequently elevated in cancer, and represent attractive targets for therapeutic intervention. |
|||
TAK-438 |
|||
A2308-100 | ApexBio | 100 mg | 2008.8 EUR |
Description: TAK-438 is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits gastric H+, K+-ATPase, [1] [2] with ID50 values of 0.86 mg/kg to histamine-stimulated acid secretion in anesthetized rats [1]. |
|||
TAK-438 |
|||
A2308-25 | ApexBio | 25 mg | 895.2 EUR |
Description: TAK-438 is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits gastric H+, K+-ATPase, [1] [2] with ID50 values of 0.86 mg/kg to histamine-stimulated acid secretion in anesthetized rats [1]. |
|||
TAK-438 |
|||
A2308-5 | ApexBio | 5 mg | 338.4 EUR |
Description: TAK-438 is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits gastric H+, K+-ATPase, [1] [2] with ID50 values of 0.86 mg/kg to histamine-stimulated acid secretion in anesthetized rats [1]. |
|||
TAK-438 |
|||
A2308-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 474 EUR |
Description: TAK-438 is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits gastric H+, K+-ATPase, [1] [2] with ID50 values of 0.86 mg/kg to histamine-stimulated acid secretion in anesthetized rats [1]. |
|||
TAK-285 |
|||
A8528-10 | ApexBio | 10 mg | 517.2 EUR |
Description: TAK-285 is a potent inhibitor of HER2 and EGFR with IC50 value of 17 nM and 23 nM, respectively [1].EGFR (epidermal growth factor receptor) and HER2 are members of ErbB family of receptors and play an important role in stimulating its intrinsic intracellular protein-tyrosine kinase activity. |
|||
TAK-285 |
|||
A8528-5 | ApexBio | 5 mg | 321.6 EUR |
Description: TAK-285 is a potent inhibitor of HER2 and EGFR with IC50 value of 17 nM and 23 nM, respectively [1].EGFR (epidermal growth factor receptor) and HER2 are members of ErbB family of receptors and play an important role in stimulating its intrinsic intracellular protein-tyrosine kinase activity. |
|||
TAK-285 |
|||
A8528-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 428.4 EUR |
Description: TAK-285 is a potent inhibitor of HER2 and EGFR with IC50 value of 17 nM and 23 nM, respectively [1].EGFR (epidermal growth factor receptor) and HER2 are members of ErbB family of receptors and play an important role in stimulating its intrinsic intracellular protein-tyrosine kinase activity. |
|||
TAK-715 |
|||
A8688-10 | ApexBio | 10 mg | 205.2 EUR |
Description: TAK-715 is a selective inhibitor of p38 MAPK with IC50 value of 7.1 nM [1].p38 mitogen-activated protein (MAP) kinases (p38 MAPKs) are a class of mitogen-activated protein kinases and play an important role in controlling cellular responses to cytokines and stress. |
|||
TAK-715 |
|||
A8688-50 | ApexBio | 50 mg | 517.2 EUR |
Description: TAK-715 is a selective inhibitor of p38 MAPK with IC50 value of 7.1 nM [1].p38 mitogen-activated protein (MAP) kinases (p38 MAPKs) are a class of mitogen-activated protein kinases and play an important role in controlling cellular responses to cytokines and stress. |
|||
TAK-632 |
|||
A8226-10 | ApexBio | 10 mg | 212.4 EUR |
Description: TAK-632 is a selective inhibitor of BRAF, CRAF and BRAF-V600E kinase with IC50 value of 8.3 nM, 1.4 nM and 2.4 nM [1]. |
|||
TAK-632 |
|||
A8226-100 | ApexBio | 100 mg | 706.8 EUR |
Description: TAK-632 is a selective inhibitor of BRAF, CRAF and BRAF-V600E kinase with IC50 value of 8.3 nM, 1.4 nM and 2.4 nM [1]. |
|||
TAK-632 |
|||
A8226-5 | ApexBio | 5 mg | 157.2 EUR |
Description: TAK-632 is a selective inhibitor of BRAF, CRAF and BRAF-V600E kinase with IC50 value of 8.3 nM, 1.4 nM and 2.4 nM [1]. |
|||
TAK-632 |
|||
A8226-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 177.6 EUR |
Description: TAK-632 is a selective inhibitor of BRAF, CRAF and BRAF-V600E kinase with IC50 value of 8.3 nM, 1.4 nM and 2.4 nM [1]. |
|||
TAK-632 |
|||
A8226-50 | ApexBio | 50 mg | 477.6 EUR |
Description: TAK-632 is a selective inhibitor of BRAF, CRAF and BRAF-V600E kinase with IC50 value of 8.3 nM, 1.4 nM and 2.4 nM [1]. |
|||
TAK-632 |
|||
A8226-S | ApexBio | Evaluation Sample | 97.2 EUR |
Description: TAK-632 is a selective inhibitor of BRAF, CRAF and BRAF-V600E kinase with IC50 value of 8.3 nM, 1.4 nM and 2.4 nM [1]. |
|||
TAK-875 |
|||
A8339-10 | ApexBio | 10 mg | 366 EUR |
Description: TAK-875 is a potent, selective, and oral GPR40 agonist. GPR40 is one of the G protein-coupled receptors predominantly expressed in pancreatic ?-cells, mediating enhancement of glucose-stimulated insulin secretion by free fatty acids. |
|||
TAK-875 |
|||
A8339-5 | ApexBio | 5 mg | 226.8 EUR |
Description: TAK-875 is a potent, selective, and oral GPR40 agonist. GPR40 is one of the G protein-coupled receptors predominantly expressed in pancreatic ?-cells, mediating enhancement of glucose-stimulated insulin secretion by free fatty acids. |
|||
TAK-875 |
|||
A8339-5.1 | ApexBio | 10 mM (in 1mL DMSO) | 268.8 EUR |
Description: TAK-875 is a potent, selective, and oral GPR40 agonist. GPR40 is one of the G protein-coupled receptors predominantly expressed in pancreatic ?-cells, mediating enhancement of glucose-stimulated insulin secretion by free fatty acids. |
|||
TAK-875 |
|||
A8339-50 | ApexBio | 50 mg | 714 EUR |
Description: TAK-875 is a potent, selective, and oral GPR40 agonist. GPR40 is one of the G protein-coupled receptors predominantly expressed in pancreatic ?-cells, mediating enhancement of glucose-stimulated insulin secretion by free fatty acids. |